Cargando…

Survival-associated alternative splicing signatures in non-small cell lung cancer

Alternative splicing (AS) is fundamental to transcriptome and proteome richness, and data from recent studies suggested a critical association between AS and oncogenic processes. To date, no systematic analysis has been conducted on AS from the perspective of different sexes and subtypes in non-smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Deze, Zhang, Chuantao, Jiang, Man, Wang, Yongjie, Liang, Yu, Wang, Li, Qin, Kang, Rehman, Faisal UL, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185095/
https://www.ncbi.nlm.nih.gov/pubmed/32282333
http://dx.doi.org/10.18632/aging.102983
_version_ 1783526700128141312
author Zhao, Deze
Zhang, Chuantao
Jiang, Man
Wang, Yongjie
Liang, Yu
Wang, Li
Qin, Kang
Rehman, Faisal UL
Zhang, Xiaochun
author_facet Zhao, Deze
Zhang, Chuantao
Jiang, Man
Wang, Yongjie
Liang, Yu
Wang, Li
Qin, Kang
Rehman, Faisal UL
Zhang, Xiaochun
author_sort Zhao, Deze
collection PubMed
description Alternative splicing (AS) is fundamental to transcriptome and proteome richness, and data from recent studies suggested a critical association between AS and oncogenic processes. To date, no systematic analysis has been conducted on AS from the perspective of different sexes and subtypes in non-small-cell lung cancer (NSCLC). Thus, we integrated the information of NSCLC patients from The Cancer Genome Atlas (TCGA) and evaluated AS profiles from the perspectives of sex and subtype. Eventually, a total of 813 and 1020 AS events were found to be significantly related to the overall survival (OS) of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. Four prognostic prediction models performed well at 1, 3, and 5 years, with an area under the receiver operating characteristic (ROC) curve (AUC) greater than 0.75. Notably, we explored the upstream splicing factors (SFs) and downstream regulatory mechanisms of the OS-associated AS events and verified four differentially expressed alternative splicing (DEAS) events via qPCR. These findings can provide important guidance for subsequent studies. In addition, we also constructed nomograms to facilitate early screening by clinicians and to determine patient outcomes in NSCLC.
format Online
Article
Text
id pubmed-7185095
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-71850952020-05-01 Survival-associated alternative splicing signatures in non-small cell lung cancer Zhao, Deze Zhang, Chuantao Jiang, Man Wang, Yongjie Liang, Yu Wang, Li Qin, Kang Rehman, Faisal UL Zhang, Xiaochun Aging (Albany NY) Research Paper Alternative splicing (AS) is fundamental to transcriptome and proteome richness, and data from recent studies suggested a critical association between AS and oncogenic processes. To date, no systematic analysis has been conducted on AS from the perspective of different sexes and subtypes in non-small-cell lung cancer (NSCLC). Thus, we integrated the information of NSCLC patients from The Cancer Genome Atlas (TCGA) and evaluated AS profiles from the perspectives of sex and subtype. Eventually, a total of 813 and 1020 AS events were found to be significantly related to the overall survival (OS) of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. Four prognostic prediction models performed well at 1, 3, and 5 years, with an area under the receiver operating characteristic (ROC) curve (AUC) greater than 0.75. Notably, we explored the upstream splicing factors (SFs) and downstream regulatory mechanisms of the OS-associated AS events and verified four differentially expressed alternative splicing (DEAS) events via qPCR. These findings can provide important guidance for subsequent studies. In addition, we also constructed nomograms to facilitate early screening by clinicians and to determine patient outcomes in NSCLC. Impact Journals 2020-04-13 /pmc/articles/PMC7185095/ /pubmed/32282333 http://dx.doi.org/10.18632/aging.102983 Text en Copyright © 2020 Zhao et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhao, Deze
Zhang, Chuantao
Jiang, Man
Wang, Yongjie
Liang, Yu
Wang, Li
Qin, Kang
Rehman, Faisal UL
Zhang, Xiaochun
Survival-associated alternative splicing signatures in non-small cell lung cancer
title Survival-associated alternative splicing signatures in non-small cell lung cancer
title_full Survival-associated alternative splicing signatures in non-small cell lung cancer
title_fullStr Survival-associated alternative splicing signatures in non-small cell lung cancer
title_full_unstemmed Survival-associated alternative splicing signatures in non-small cell lung cancer
title_short Survival-associated alternative splicing signatures in non-small cell lung cancer
title_sort survival-associated alternative splicing signatures in non-small cell lung cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185095/
https://www.ncbi.nlm.nih.gov/pubmed/32282333
http://dx.doi.org/10.18632/aging.102983
work_keys_str_mv AT zhaodeze survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT zhangchuantao survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT jiangman survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT wangyongjie survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT liangyu survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT wangli survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT qinkang survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT rehmanfaisalul survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer
AT zhangxiaochun survivalassociatedalternativesplicingsignaturesinnonsmallcelllungcancer